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Summary: Bone marrow transplant recipients may carry an increased risk of bone diseases, involving numerous
factors that affect bone mineral metabolism. Interleukin-6 is a potent stimulator of bone resorption in vivo. The
soluble fraction of interleukin-6 receptor is reported to trigger osteoclast formation by interleukin-6 in vitro.
In a cross-sectional study we measured serum bone alkaline phosphatase concentrations and the urinary excretion
of pyridinium cross-links in 21 patients after bone marrow transplantation, and investigated the relationship between
these values and those for the plasma levels of interleukin-6 and soluble interleukin-6 receptor.
Following bone marrow transplantation female — but not male — patients showed higher serum bone alkaline
phosphatase values than age- and sex-adjusted controls (p < 0.05). Both female and male patients were charac-
terized by increased urinary excretion values of pyridinium cross-links (p < 0.05). In contrast to a marked increase
of interleukin-6 plasma levels (p < 0.001) no significant difference in the soluble interleukin-6 receptor levels was
found between patients and apparently healthy persons (p = 0.838). Multiple regression analysis (taking into ac-
count different variables of the immunosuppressive regimen applied) revealed the plasma concentration of interleu-
kin-6 as an independent predictor of the urinary excretion of pyridinium cross-links (p < 0.05).
In conclusion, in patients following bone marrow transplantation, these findings indicate
(a) an increase of bone formation in female — but not in male — patients possibly reflecting primary ovarian
failure and
(b) an enhancement of bone resorption possibly mediated by circulating interleukin-6.
Introduction Following bone marrow transplantation, plasma in-
_, . · · * ± - j · ι terleukin-6 levels are regularly raised in febrile episodesBone marrow transplant recipients are at increased risk · j · i. i_ · j · * j-., ,. 5 , /f (3) and associated with the induction of acute andof bone diseases for several reasons (for review see / Δ . ,.. _, . ,.chronic graft-versus-host reaction (4). Several studies m
vitro (5, 6) and in vivo (7, 8, 9) have shown that in-
(a) Sex hormone deficiency increases bone loss, espe- terleukin-6 is a potent stimulator of bone resorption. In-
cially in women following pretransplant conditioning terleukin-6 exerts its activity via a cell surface receptor
with total body irradiation or chemotherapy; which consists of two components: a ligand-binding MT
/u\ η ^ ·Λ Λ- * + - u A 80000 glycoprotein chain (interleukin-6 receptor) and(b) Glucocorticoids predispose to osteopema by de- ,. .ί · „· , · , ^ . , /ΛΛΛΛ
u r . .. Λ . u a non-ligand binding but signal-transducing Mr 130000pressing bone formation a n d increasing bone resorp- t 6 . , . ? , „ * , . , , ,. . glycoprotein chain (gp!30). It has been shown that the
soluble fraction of interleukin-6 receptor which lacks
(c) Cyclosporin A is known to produce high bone re- transmembrane and cytoplasmic regions can also medi-
modelling with bone resorption exceeding bone forma- ate the interleukin-6 signal through gp!30 (5). The solu-
tion and can therefore induce osteopenia when applied ble fraction of interleukin-6 receptor is reported to trig-
in immunosuppressive doses. ger osteoclast formation by interleukin-6 in vitro (5).
Reduced bone mineral density in patients following In the present study bone turnover in patients following
bone marrow transplantation has already been shown bone marrow transplantation was assessed by measuring
(2). serum mass concentrations of bone alkaline phosphatase
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(EC 3.1,3.1) (a marker of bone formation) and the uri-
nary excretion of pyridinium cross-links (a marker of
bone resorption).' The resulting values were compared
with the plasma levels of interleukin-6 and the soluble
fraction of its receptor.
Patients and Methods
Pat ients
We examined 177 blood and 44 urine samples from 21 patients
after bone marrow transplantation (age: 36.1 ± 2.0 years) (mean
± SEM) (13 males, 8 females) (8 chronic granulocyte leukaemia, 4
acute non-lymphoblastic leukaemia, 5 'high-grade' non-Hodgkinys
lymphoma, 1 Hodgkin's lymphoma, 1 acute lymphoblastic leukae-
mia, 1 refractory anaemia and 1 multiple myeloma). Eighteen pa-
tients received allogeneic bone marrow transplantation whereas
three patients received autologous bone marrow transplantation.
The mean time since transplantation was 281 ±16 days (mean
± SEM). The number of blood/urine samples obtained from each
patient ranged from 3 to 29 (mean: 9).
Conditioning regimens
Seventeen patients received pretransplant conditioning with total
body irradiation (2 Gy X 6 or 2.5 Gy X 4) and 'high-dose' cyclo-
phosphamide (120—180 mg/kg - d). In four patients cyclophospha-
mide was given alone. Furthermore, etoposide (VP-16) 10-25 mg/
kg · d X 2 was given in 10 patients and 1.3-bis(2-chloroethyl)-l-
nitrosourea 5 mg/kg · d in 4 patients.
Graft-versus-host disease prophylaxis and therapy
To prevent graft-versus-host disease, patients undergoing allogen-
eic bone marrow transplantation received cyclosporin A (4 mg/
kg · d i. v. for 35 ±3 days, then 12 mg/kg · d p.o. for 271 ± 21
days) (mean ± SEM) and 'short-term' methotrexate (15 mg/m2 at
day 1 and 10 mg/m2 at days 3 and 6 after bone marrow transplanta-
tion). Cyclosporin A concentrations in whole blood were 200-300
μg/l in the first six months after bone marrow transplantation. Five
of the patients received prednisolone 1 — 1.5 mg/kg · d p. o.
All female patients following bone marrow transplantation had
clinical and biochemical evidence of primary ovarian failure. None
of the patients had clinical or biochemical signs of disturbed vita-
min D or phosphate metabolism. Moreover, none of the patients
had had any bone disease before transplantation [bone density mea-
surements (using dual-energy X-ray absorptiometry) performed be-
fore transplantation yielded values within the reference range both
at the lumbar spines as well as at the femoral neck (as compared
with sex- and age-adjusted controls)].
Methods
Bone alkaline phosphatase mass concentration in serum was deter-
mined by an immunoradiometric assay (Tandem®-R Ostase™; Hy-
britech Inc., San Diego, CA [U. S. A.]; no. 3040 BE) employing
two monoclonal antibodies against two different epitopes of the
bone alkaline phosphatase molecule. A calibration curve was con-
structed by linear interpolation between the plotted analytical re-
sults. The following reference intervals (mean ± 2 X SD) for bone
alkaline phosphatase concentrations in serum were established in
apparently healthy persons: (1) 3.2-15.8 μg/l (males, n = 38) (2)
2.3-12.2 μg/l (females, n = 47). Age-range was 27-51 years
(males) and 19-48 years (females). Bone alkaline phosphatase
values were higher in males than in females (p < 0.0001).
The urinary excretion of pyridinium cross-links was determined by
a competitive enzyme immunoassay (Collagen Crosslinks™ Kit;
Metra Biosystems Inc.; Palo Alto, CA [U. S. A.]) employing a poly-
clonal antibody against pyridinoline which shows 100% cross-re-
activity with deoxypyridinoline. A curve was constructed employ-
ing a 4-parameter curve fitting equation. The following reference
interval (mean ± 2 X SD) for the urinary excretion of pyridinium
cross-links in second morning urine samples was established in
apparently healthy persons (the samples were obtained between
8.00 and 10.00 a.m.): pyridinoline equivalents, 12-73 μπιοΐ/πιοί
creatinine (n = 75; 33 males and 42 females; age-range: 20-56
years). There was no dependence of reference values upon sex.
Plasma levels of interleukin-6 were determined with an enzyme
immunoassay (Quantikine™ HS Human-IiL-6 Immunoassay; R&
D Systems; Minneapolis, MN [U. S. A.]). The upper reference limit
(mean H- 2 X SD; n = 23; 17 males and 6 females) was 2.4 ng/1.
The soluble plasma fraction of interleukin-6 receptor was deter-
mined with an enzyme immunoassay (Quantikine™ Human IL-6
sR Immunoassay; R&D Systems; Minneapolis, MN [U.S.A.]).
The reference interval (mean ± 2 X SD; n = 23; 17 males and 6
females) was 9.7-67.4 μg/l.
The potassium salt of ethylenediaminetetraacetic acid was used as
anticoagulant in the latter two tests.
Statistical analysis
The statistical methods employed included the U-test according to
Mlcoxon, Mann & Wlutney (two-tailed) for unpaired samples and
linear correlation coefficients (10). Multiple regression analysis
was performed with SPSS/PC+ V2.0 employing the procedure
REGRESSION with a 'stepwise' selection of the independent vari-
ables.
Results
Comparison of mean values obtained from each patient
revealed that following bone marrow transplantation, fe^
male — but not male — patients showed higher serum
bone alkaline phosphatase values than age- and sex-ad-
justed controls (p < 0.05). After bone marrow transplant
tation both female and male patients showed a higher
urinary excretion of pyridinium cross-links than appar-
ently healthy persons (p < 0.05). There was a lack of
correlation between serum bone alkaline phosphatase
values and the urinary excretion of pyridinium cross-
links (p = 0.562) (tab. 1 and fig. la,b). No correlation
was observed between the values of these two biochemi-
Tab. l Z score analysis of biochemical markers of bone metabo-
lism and plasma cytokine levels in patients following bone marrow
transplantation.
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Ζ SCOre = ^mganPatients aftc'r transplantation "" rneanreference individuals)
SDreference individuals
For characterisation of the reference individuals see under Patients
and Methods. The age of the reference individuals did not signifi-
cantly differ from that of the patients (p > 0.05).
* p < 0.05
*** p < 0.001 ;
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cal markers of bone metabolism (measured after trans-
plantation) and bone mineral density (at lumbar spines
or femoral neck) (obtained before transplantation)
(p > 0.05).
Following bone marrow transplantation there was a
marked increase of interleukin-6 plasma levels
(p < 0.001) but no significant difference in the soluble
plasma fraction of its receptor between patients and ap-
parently healthy persons (p = 0.838). Both in apparently
healthy persons as well as in patients following bone
marrow transplantation there was a lack of correlation
between plasma interleukin-6 concentrations and the
soluble plasma fraction of its receptor (p > 0.5) (tab. 1
and fig. Ic, d).
There was no correlation between the values of pyridin-
ium cross-links excretion, plasma interleukin-6 and
plasma soluble interleukin-6 receptor levels on the one
hand and time after transplantation on the other
(p > 0.05), whereas a significant increase of serum bone
alkaline phosphatase was observed within the first year
after transplantation (p < 0.01).
Bivariate analysis showed a significant correlation be-
tween the urinary excretion of pyridinium cross-links
and plasma interleukin-6 concentrations (tab. 2). To as-
sess other possible influences upon the urinary excretion
of pyridinium cross-links, the relative effects of the
following independent variables were determined by
multiple regression analysis:
Tab. 2 Correlation coefficients between biochemical markers of




Serum bone alkaline phosphatase vs r = - 0.124
plasma interleukin-6 concentrations p > 0.05
Serum bone alkaline phosphatase vs r = — 0.088
plasma interleukin-6 receptor concentration p > 0.05
Urinary excretion of pyridinium cross-links vs r = + 0.389
plasma interleukin-6 concentration p = 0.012
Urinary excretion of pyridinium cross-links vs r = + 0.285
plasma interleukin-6 receptor concentration p > 0.05
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Fig. 1 Relationship between biochemical marker values of bone
metabolism/plasma cytokine levels and time after transplantation
in patients following bone marrow transplantation.
The shaded areas denote the reference interval (mean ± 2 X SD)
(for characterisation of the reference individuals see Patients and
Methods). For bone alkaline phosphatase concentrations the depen-
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Time after transplantation [d]
=· 80
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dence of the reference values upon sex was not considered. Data
pairs belonging to the same patients are connected by lines. Sam-
ples obtained from female patients are designated by asterisks,
those from male patients by dots.
The pyridinium cross links content is referred to creatinine.
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(a) plasma interleukin-6 concentration;
(b) cumulative dose of cyclosporin A and duration of
cyclosporin A therapy;
(c) cumulative dose of prednisolone, dose of predniso-
lone at the day of sample collection and duration of
prednisolone therapy.
The plasma concentration of interleukin-6 was the only
independent predictor of the urinary excretion of pyri-
dinium cross-links (p < 0.05) (tab. 3).
Discussion
In female, but not in male patients, there was a signifi-
cant increase in the serum bone alkaline phosphatase
values as compared with age- and sex-matched controls.
This may be explained by the influence of primary ovar-
ian failure following total body irradiation, whereas in
men only a moderate elevation of gonadotropins and tes-
tosterone within the reference interval were observed (2,
11). Cyclosporirji A may enhance the deleterious effect
of oestrogen deficiency, since in oophorectomised rats
bone mass loss is accelerated by the application of
cyclosporin A (12).
Carlson et al. (13) found a depression of bone formation
within the first three months following bone marrow
transplantation, which is probably due to
(a) an inhibitory effect of glucocorticosteroids upon
bone formation,
(b) damage of osteoprogenitor cells by the myeloabla-
tive therapy and
(c) inhibition of osteoblast function by locally secreted
cytokines. However, the follow-up period of this study
was only 3 months after bone marrow transplantation,
whereas in the present communication the mean time
since transplantation was 281 days.
Reduced bone mineral density is a common finding in
patients following liver, cardiac and bone marrow trans-
plantation (2, 14, 15, 16). This is in concordance with
our findings of increased values of both bone formation
Tab. 3 Independent predictor variables for the urinary excretion




















Significance refers to the p value at final step.
and bone resorption, indicating increased bone turnover.
Interestingly no correlation was found between bone al-
kaline phosphatase mass concentrations in serum and
the urinary excretion of pyridinium cross-links. This is
in contrast to previous findings of our group, as well as
others, in patients with primary (17) or secondary (18)
hyperparathyroidism and bone metaStases (19, 20), indi-
cating that in patients after bone marrow transplantation
different influencing factors may affect bone formation
and resorption, respectively.
A multivariate statistical approach revealed the plasma
concentration of interleukin-6 as an independent predic-
tor of the urinary excretion values of pyridinium cross-
links, whereas there is no augmenting effect of the solu-
ble interleukin-6 receptor upon bone metabolism in pa-
tients undergoing bone marrow transplantation. In con-
trast, Tamura et al. (5) found that only simultaneous
treatment with interleukin-6 and soluble interleukin-6
receptor induces formation of osteoclast4ike cells in
vitro.
Several authors have observed that interleukin-6 en-
hances bone resorption in vivo:
(a) Inoculation of nude mice with Chinese hamster
ovarian cells, which have been transfected with the mu-
rine interleukin-6 gene, induces hypercalcaemia (7);
(b) Neutralising antibodies directed against interleukin-
6 reverse hypercalcaemia associated with a human carci-
noma cell line transplanted in nude mice (8);
(c) In oophorectomised rats, increased osteoclast devel-
opment is mediated by interleukin-6 (9).
Recently, Khosla et al. (21) found that postmenopausal
women did not show higher plasma interleukin-6 levels
as compared with premenopausal women. However, the
interleukin-lo/interleukin-1 receptor antagonist concen-
tration ratio was significantly increased in postmeno-
pausal women (21), suggesting a possible effect of cy-
tokines upon bone metabolism in postmenopausal
women.
In conclusion, our findings suggest two variables possi-
bly acting on bone metabolism in patients after bone
marrow transplantation:
(1) Increase of bone formation in female - but not male
— patients, possibly reflecting primary ovarian failure;
(2) Enhancement of bone resorption possibly mediated
by circulating interleukin-6. However, it is admitted that
numerous factors can affect bone mineral metabolism
in patients undergoing organ transplantation (e. g., long-
term parenteral nutrition, disturbances of vitamin D and
phosphate metabolism, action of drugs) which may be
difficult to differentiate in cross-sectionally designed
clinical studies (1).
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